clinical trial · NCT00781274
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
Hepatitis CMP-424RibavirinPeginterferon Alfa-2b
brief summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.
started
Dec 1, 2008
primary completion
Jul 1, 2010
completion
Jul 1, 2010
last updated
Jan 6, 2026
official title
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol